XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.22.1

Financial Instruments | 3 Months Ended
--- | ---
Mar. 31, 2022
Investments, All Other Investments [Abstract] |
Financial Instruments | 4. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2022, and December 31, 2021: Schedule of Cash and Marketable Securities by Significant Investment Category
|  | 2022 |
|  | Adjusted Cost |  |  | Unrealized Gain/(Loss) |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Marketable Securities |  |  | Investments |
Cash |  | $ | 48,799,000 |  |  | $ | - |  |  | $ | 48,799,000 |  |  | $ | 48,799,000 |  |  | $ | - |  |  | $ | - |
Level 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money Market Funds |  |  | 5,012,000 |  |  |  | - |  |  |  | 5,012,000 |  |  |  | 5,012,000 |  |  |  | - |  |  |  | - |
Marketable Securities |  |  | 15,865,000 |  |  |  | 2,570,000 |  |  |  | 18,435,000 |  |  |  | - |  |  |  | 18,435,000 |  |  |  | - |
Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  | 3,318,000 |  |  |  | - |  |  |  | 3,318,000 |  |  |  | - |  |  |  | - |  |  |  | 3,318,000 |
Convertible securities |  |  | 1,023,000 |  |  |  | 357,000 |  |  |  | 1,380,000 |  |  |  | - |  |  |  | - |  |  |  | 1,380,000 |
Total |  | $ | 74,017,000 |  |  | $ | 2,927,000 |  |  | $ | 76,944,000 |  |  | $ | 53,811,000 |  |  | $ | 18,435,000 |  |  | $ | 4,698,000 |
|  | 2021 |
|  | Adjusted Cost |  |  | Unrealized Gain/(Loss) |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Marketable Securities |  |  | Investments |
Cash |  | $ | 50,286,000 |  |  | $ | - |  |  | $ | 50,286,000 |  |  | $ | 50,286,000 |  |  | $ | - |  |  | $ | - |
Level 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money Market Funds |  | $ | 6,309,000 |  |  |  | - |  |  |  | 6,309,000 |  |  |  | 6,309,000 |  |  |  | - |  |  |  | - |
Marketable Securities |  | $ | 12,993,000 |  |  |  | 1,544,000 |  |  |  | 14,537,000 |  |  |  | - |  |  |  | 14,537,000 |  |  |  | - |
Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  | $ | 3,318,000 |  |  |  | - |  |  |  | 3,318,000 |  |  |  | - |  |  |  | - |  |  |  | 3,318,000 |
Convertible securities |  | $ | 1,023,000 |  |  |  | - |  |  |  | 1,023,000 |  |  |  | - |  |  |  | - |  |  |  | 1,023,000 |
Total |  | $ | 73,929,000 |  |  | $ | 1,544,000 |  |  | $ | 75,473,000 |  |  | $ | 56,595,000 |  |  | $ | 14,537,000 |  |  | $ | 4,341,000 |
The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration